91.5 Chapel Hill 88.9 Manteo 90.9 Rocky Mount 91.1 Welcome 91.9 Fayetteville 90.5 Buxton 94.1 Lumberton 99.9 Southern Pines 89.9 Chadbourn

Pfizer Drops $119 Billion Bid For AstraZeneca

Your browser doesn’t support HTML5 audio

William Vazquez

It would have been the biggest deal the pharmaceutical industry has seen in more than a decade. But for now, it's off the table.

Pfizer has withdrawn its offer to buy British drug company AstraZeneca for about $119 billion.

American pharmaceutical giant Pfizer, which makes Lipitor and Viagra, has been circling its smaller rival AstraZeneca for months.

AstraZeneca, which makes Nexium and Crestor, has rejected every offer saying Pfizer undervalues the company, and that it wants to remain independent.

There were fears that jobs and research facilities in the UK would be lost.

Had the deal gone through, Pfizer could have reincorporated in Britain and taken advantage of lower taxes.

Inversions as they're called, annoy members of Congress who say they erode the U.S. corporate tax base.

Both companies face stiff competition in the future as more and more people turn to less expensive, generic drugs.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

  • Facebook
  • Twitter
  • LinkedIn
  • Email
Elizabeth Blair is a Peabody Award-winning senior producer/reporter on the Arts Desk of NPR News.
More Stories
  1. Israel raids Al Jazeera office as Netanyahu government votes to shut channel down
  2. In 'The Fall Guy,' stunts finally get the spotlight
  3. Ukraine's Zelenskyy calls God an "ally" against Russia in Orthodox Easter message
  4. When rockets fall, Bedouin Israeli citizens have nowhere to hide
  5. Mystik Dan wins the Kentucky Derby by a nose